Illumina (NASDAQ:ILMN) raised its 2026 revenue and earnings outlook after reporting second-quarter results that exceeded its expectations, supported by clinical sequencing demand, elevated NovaSeq X placements and higher consumables volume.
Second-quarter revenue totaled $1.16 billion, up 9.5% from
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s...
Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. ...
Genomics company Illumina (NASDAQ:ILMN) will be announcing earnings results this Thursday after market close. Here’s what to expect. Illumina beat analysts’ ...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 1.9% in the afternoon session after Swiss drugmaker Roche launched a next-generation ge...
What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to ...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destocking...
Illumina has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15% to $140.33 pe...
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
